Articles From: Zoetis Declares Third Quarter 2014 Dividend to zulily to Participate at Citi Global Technology Conference


The Board of Directors of Zoetis Inc. (NYSE:ZTS) declared a third quarter dividend payable to holders of the company’s common stock of $0.072 per share.
Sign-up for Zoetis Declares Third Quarter 2014 Dividend investment picks
Zoetis Inc. (NYSE:ZTS) today announced that the U.S. Department of Agriculture (USDA) has granted a conditional license for a vaccine to help fight porcine epidemic diarrhea virus (PEDv) in pigs.
Sign-up for Zoetis Granted Conditional License for Porcine Epidemic Diarrhea Vaccine* investment picks
Zoetis Inc. (NYSE:ZTS) today reported its financial results for the second quarter of 2014.
Sign-up for Zoetis Reports Second Quarter 2014 Results investment picks
Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (EDT) on Tuesday, August 5, 2014.
Sign-up for Zoetis to Host Webcast and Conference Call on Second Quarter 2014 Financial Results investment picks
Zoetis Inc. (NYSE:ZTS) will participate in the Bank of America Merrill Lynch Global Healthcare Conference on Thursday, Sept.
Sign-up for Zoetis to Participate in Bank of America Merrill Lynch Global Healthcare Conference investment picks
Zoetis Inc. (NYSE:ZTS) will participate in the Morgan Stanley Global Healthcare Conference on Wednesday, Sept.
Sign-up for Zoetis to Participate in Morgan Stanley Global Healthcare Conference investment picks
Zoetis Inc. (NYSE:ZTS) today announced it will hold its inaugural Investor Day for financial analysts on Tuesday, Nov.
Sign-up for Zoetis Will Hold Its Inaugural Investor Day on November 18 investment picks
SAN DIEGO, July 17, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) , a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central nervous system disorders, today announced that David Brushwood, J.D., R.Ph., recently-retired Professor Emeritus of Pharmaceutical Outcomes and Policy at the University of Florida, College of Pharmacy, has joined the company's External Safe Use Board.
Sign-up for Zogenix Announces Appointment of David Brushwood, J.D., R.Ph., to External Safe Use Board investment picks
SAN DIEGO, July 22, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) , a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced it will release financial results for the second quarter ended June 30, 2014, after the market closes on Tuesday, August 5, 2014, and will hold a conference call on this day at 4:30 p.m. ET (1:30 p.m. PT), to discuss these financial results and provide a company update.
Sign-up for Zogenix Announces Conference Call and Webcast to Present Second Quarter 2014 Financial Results investment picks
SAN DIEGO, Aug.
Sign-up for Zogenix Announces Departure of Chief Commercial Officer, Scott Shively investment picks
SAN DIEGO, July 14, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) announced today the issuance of a new patent, US 8,734,384, from the United States Patent and Trademark Office (USPTO). The patent covers the biphasic pressure profile utilized by the company's proprietary DosePro ® Needle-free Delivery System.
Sign-up for Zogenix Announces New Patent Valid Through 2032 For DosePro(R) Needle-Free Delivery System investment picks
SAN DIEGO, July 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today announced an update on its development programs focused on the introduction of abuse deterrent formulations of Zohydro ® ER (hydrocodone bitartrate) Extended-Release Capsules, CII.
Sign-up for Zogenix Provides Update on Development of Abuse Deterrent Formulations of Zohydro(R) ER investment picks
SAN DIEGO, July 9, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) today commented on the order issued by the U.S. District Court in Massachusetts upholding its prior decision that imposing regulations to restrict access to Zohydro ® ER (hydrocodone bitartrate) Extended-Release Capsules, CII, violates Constitutional law.
Sign-up for Zogenix Reports Positive Development on U.S. District Court Ruling investment picks
Recent Business Highlights Second Quarter 2014 Highlights Total prescriptions for Zohydro ER were 10,299 for the second quarter; 4,076 for the first four weeks of July, up 74% compared to the first four weeks of April; and 1,088 for the most recent week ended July 25 1 Total net revenue of $9.2 million Zohydro ER net revenue of $2.4 million on prescription demand Zohydro ER gross factory sales to wholesalers of $4.8 million during the second quarter; $11.6 million year-to-date SAN DIEGO, Aug.
Sign-up for Zogenix Reports Second Quarter 2014 Financial Results investment picks
SAN DIEGO, Sept.
Sign-up for Zogenix to Participate in Morgan Stanley Global Healthcare Conference 2014 investment picks
SAN DIEGO, June 16, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX) , a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system (CNS) disorders, today announced that Ann Rhoads, Chief Financial Officer, will be presenting at two upcoming institutional investor conferences.
Sign-up for Zogenix to Present at Two Upcoming Conferences investment picks
SAN DIEGO, Sept.
Sign-up for Zohydro(R) ER Demonstrates Sustained 12-Hour Pain Relief investment picks
BEIJING, Aug.
Sign-up for Zoom Technologies - Late Filing of 2014 Q2 Report investment picks
COPPELL, Texas, Aug.
Sign-up for ZS Pharma Announces Second Quarter 2014 Financial Results investment picks
COPPELL, Texas, July 17, 2014 (GLOBE NEWSWIRE) -- ZS Pharma (Nasdaq:ZSPH) , a biopharmaceutical company developing novel treatments for kidney, cardiovascular, liver and metabolic disorders, today announced that it has secured a debt facility of up to $20 million with MidCap Financial.
Sign-up for ZS Pharma Secures $20 Million in Debt Financing investment picks
2014/8/26
LitePoint , a leading provider of wireless test solutions, announced today that ZTE Corporation has adopted LitePoint’s cellular and connectivity test solutions for calibrating and verifying their latest 4G smartphones in production.
Sign-up for ZTE Adopts LitePoint Solutions for LTE Smartphone Production Test investment picks
Marvell's quad-core ARMADA Mobile PXA1920 continues to lead in China's fast expanding 4G LTE market with the new ZTE Q805T smartphone SANTA CLARA, Calif.
Sign-up for ZTE Launches 5-Mode 4G LTE Mass Market Smartphone for China Mobile Powered by Marvell investment picks
2014/6/26
SAN FRANCISCO (MarketWatch) -- Tech stocks were mixed in early trading Thursday, with most of the notable gainers coming from the Internet sector.
Sign-up for Zulily among Internet gainers; market awaits GoPro debut investment picks
2014/8/6
Q2 Net Sales Increased 97% year over year to $285.0 million Q2 Active Customers Increased 86% year over year to 4.1 million Q2 Non-GAAP Adjusted EBITDA of $14.4 million Q2 Non-GAAP Diluted Net Income per Share of $0.09 SEATTLE, Aug.
Sign-up for zulily Announces Second Quarter 2014 Results; Raises Full Year Revenue Guidance investment picks
2014/8/29
SEATTLE, Aug.
Sign-up for zulily Announces September 11, 2014 Webcast From Newly Automated Ohio Fulfillment Center investment picks
2014/6/26
By Rex Crum, MarketWatch SAN FRANCISCO (MarketWatch) -- Tech stocks mostly retreated Thursday, with the notable exception of online retailer Zulily Inc., on a day in which many investors await the public debut of digital-sport camera maker GoPro Inc. Zulily (ZU) rose almost 3% to $40.97 after RBC Capital Markets analyst Mark Mahaney raised his rating on the online retailer of clothing for children and women to outperform from sector perform.
Sign-up for Zulily rises, GoPro awaits public debut investment picks
2014/8/19
SEATTLE, Aug.
Sign-up for zulily to Participate at Citi Global Technology Conference investment picks
Start Premium Trial Register For Free

P F Fund Financial Data (13,000+ funds)
P F Stock Financial Data (7,000+ stocks)
P F Stock and Fund Screeners (basic)
P F Investing Articles and Market Commentary
P F Articles Archive (>30 days)
P F Discuss (dozens of stock, fund, bond, and general bulletin boards)
P F Portfolio Manager (basic)
P F Morningstar Investment Classroom
P F Access Your Portfolio Anytime, Anywhere via Your Mobile Device
P   Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)
P   Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)
P   Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)
P   Portfolio Monitor (monthly and on-demand personalized portfolio statements)
P   Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)
P   Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters
P   Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)
P   Discounts on Morningstar newsletters, books, seminars, and more

Sign-up to Morningstar


Basic Access

Articles and Videos
Morningstar video reports, articles, data, and tools. Dig into our lineup of e-newsletters and investing classroom courses outlining sensible strategies for maximizing your investments.
Morningstar Discuss
Follow the buzz on individual stocks or fund families. Plus, read the latest posts from Morningstar members and analysts.
Portfolio Manager
Track your investments and watch lists with our Portfolio Manager. Customize your view with our comprehensive stock, fund, and ETF data.

Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.

Unlimited Access

Analyst Research
Gather in-depth, actionable insight on over 3,700 stock and mutual funds covered by Morningstar analysts. View our mutual fund Analyst Reports favored by professionals, savvy experienced investors, and new investors researching options for retirement savings, college plans, or other investment needs.
Portfolio X-Ray®
Ensure your portfolio is positioned exactly how you want with Morningstar's X-Ray Interpreter and Stock Intersection tools. A Barron's "Best of the Web" award winner for five years running, X-Ray Interpreter goes under the hood of your portfolio to provide a useful allocation, sector, and geographic analysis. And you can discover how much of a stock you really own, individually and through mutual funds, with Stock Intersection.
Investment Picks
Find new 5-star stocks (greatly undervalued companies) to consider daily. Our 5-star stock rating is a proven winner, consistently beating benchmarks like the S&P 500. Plus, browse our Fund Analyst Picks and Stewardship Grades to find shareholder-friendly mutual funds that are poised for outperformance.
Portfolio Monitor
Get a clear view of your investments with personalized reports about your portfolio. Receive monthly statements and generate reports on-demand to help you stay on track to meet your investment goals.

Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.

Articles From: Zoetis Declares Third Quarter 2014 Dividend to zulily to Participate at Citi Global Technology Conference
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices